ADUS Price Prediction Next Week
Analysis and Insights
Technical Analysis:
ADUS is currently trading at $90.91 as of the latest close on 2025-03-24. The stock is in a bearish trend, with the price below its 20, 50, 60, 200, and 250-day moving averages. The Relative Strength Index (RSI) is at 26.76, indicating oversold conditions, which may signal a potential bounce. The MACD is also negative, confirming bearish momentum.
Fibonacci Levels:
The Fibonacci pivot level is at $93.05, which could act as a resistance level. The first resistance level is at $96.58, while the first support level is at $89.52.
News Sentiment and Analyst Outlook:
RBC Capital maintains an Outperform rating on ADUS with a price target of $136, suggesting confidence in the stock's long-term growth despite recent weakness. Validea's Benjamin Graham strategy has upgraded ADUS to an 86% rating, indicating strong value based on low P/B and P/E ratios.
Conclusion:
Based on the oversold RSI and potential for a technical bounce, ADUS is expected to rise to $93.05 in the next trading week. The stock is a buy at current levels, as the positive analyst sentiment and value metrics suggest a rebound.
ADUS Similar Chart Price Prediction
The price of ADUS is predicted to go up -70.85%, based on the high correlation periods with LIQT. The similarity of these two price pattern on the periods is 99.29%.
ADUS
LIQT
Down: -70.85%Similarity: 99.29%
ADUS Revenue Forecast
ADUS EPS Forecast
ADUS FAQs
What is ADUS revenue forecast for next quarter？
What is ADUS eps forecast for next quarter？
ADUS Analyst's Forecast
Michael Wiederhorn
Oppenheimer
Buy
2024-09-23
Price Target
$140 → $145
Upside
+9.15%
Oppenheimer raised the firm's price target on Addus HomeCare to $145 from $140 and keeps an Outperform rating on the shares after hosting meetings with management and as the firm remains bullish on the story heading into year-end. Overall, Addus is seeing improving operating trends, as turnover and productivity continue to rebound from the pandemic-era lows, Oppenheimer says. Meanwhile, Addus remains optimistic around the M&A pipeline, with the Gentiva deal slated to close in Q4 2024. Overall, the firm continues to believe that Addus is attractively positioned, and would continue to be a long-term buyer.
